Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 2/20 | 0.43 |
| ▸ | MAOA | P21397 | 2/20 | 0.41 |
| ▸ | MAOB | P27338 | 2/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.38 |
| ▸ | AURKA | O14965 | 1/20 | 0.38 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.38 |
| ▸ | KIT | P10721 | 10/20 | 0.36 |
| ▸ | BRAF | P15056 | 10/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | NAMPT | P43490 | 1/20 | 0.35 |
| ▸ | STIM1 | Q13586 | 1/20 | 0.35 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.35 |
| ▸ | FLT1 | P17948 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3872452 | 0.90 | KIT (0.46) | NOTUMMAOAMAOBBRD4CREBBP | |
| SCHEMBL3872449 | 0.89 | KIT (0.48) | NOTUMMAOAMAOBBRD4CREBBP | |
| SCHEMBL1488663 | 0.86 | NOTUM (0.41) | NOTUMMAOAMAOBBRD4CREBBP | |
| SCHEMBL1488991 | 0.86 | NOTUM (0.48) | NOTUMBRD4CREBBPKITBRAF | |
| SCHEMBL13714573 | 0.83 | IRAK4 (0.39) | NOTUMAURKAAURKBKITBRAF | |
| SCHEMBL3865807 | 0.79 | FLT1 (0.50) | NOTUMKITBRAFFLT1KDR | |
| SCHEMBL3872701 | 0.76 | NOTUM (0.49) | NOTUMKITBRAFFLT1KDR | |
| SCHEMBL3867387 | 0.76 | KIT (0.51) | KITBRAFFLT1KDR | |
| SCHEMBL3873766 | 0.76 | KIT (0.59) | NOTUMBRD4CREBBPKITBRAF | |
| SCHEMBL3869318 | 0.76 | NOTUM (0.50) | NOTUMKITBRAFFLT1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110124680-A1 | NOVEL ANTHRANILAMIDE PYRIDINUREAS AS VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) RECEPTOR KINASE INHIBITORS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2011-05-26 | — | — | US | disclosed |
| US-20110124680-A1 | NOVEL ANTHRANILAMIDE PYRIDINUREAS AS VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) RECEPTOR KINASE INHIBITORS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2011-05-26 | — | — | US | disclosed |
| US-20110124680-A1 | NOVEL ANTHRANILAMIDE PYRIDINUREAS AS VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) RECEPTOR KINASE INHIBITORS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2011-05-26 | — | — | US | disclosed |
| US-7902229-B2 | Anthranilamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors | BAYER SCHERING PHARMA AG (DE) | 2011-03-08 | — | — | US | disclosed |
| US-7902229-B2 | Anthranilamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors | BAYER SCHERING PHARMA AG (DE) | 2011-03-08 | — | — | US | disclosed |
| US-7902229-B2 | Anthranilamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors | BAYER SCHERING PHARMA AG (DE) | 2011-03-08 | — | — | US | disclosed |
| US-7572794-B2 | 4-hydroxy-4-methyl-piperidine-1 -carboxylic acid (4-{[2-(2-methyl-2H-indazol-6-ylcarbamoyl)-phenylamino]-methyl}-pyridin-2-yl)-amide; 2,6-dimethyl-morpholine-4-carboxylic acid (4-{[2-(1-methyl-1H-indazol-6-ylcarbamoyl)-phenylamino]-methyl}-pyridin-2-yl)-amide | BAYER SCHERING PHARMA AG (DE) | 2009-08-11 | — | — | US | disclosed |
| US-7572794-B2 | 4-hydroxy-4-methyl-piperidine-1 -carboxylic acid (4-{[2-(2-methyl-2H-indazol-6-ylcarbamoyl)-phenylamino]-methyl}-pyridin-2-yl)-amide; 2,6-dimethyl-morpholine-4-carboxylic acid (4-{[2-(1-methyl-1H-indazol-6-ylcarbamoyl)-phenylamino]-methyl}-pyridin-2-yl)-amide | BAYER SCHERING PHARMA AG (DE) | 2009-08-11 | — | — | US | disclosed |
| US-7572794-B2 | 4-hydroxy-4-methyl-piperidine-1 -carboxylic acid (4-{[2-(2-methyl-2H-indazol-6-ylcarbamoyl)-phenylamino]-methyl}-pyridin-2-yl)-amide; 2,6-dimethyl-morpholine-4-carboxylic acid (4-{[2-(1-methyl-1H-indazol-6-ylcarbamoyl)-phenylamino]-methyl}-pyridin-2-yl)-amide | BAYER SCHERING PHARMA AG (DE) | 2009-08-11 | — | — | US | disclosed |
| CN-101056871-A | Novel anthranilamide pyridinureas as vegf receptor kinase inhibitors | BAYER SCHERING PHARMA AG (DE) | 2007-10-17 | — | — | CN | disclosed |
| EP-1807413-A1 | ANTHRANILAMIDE PYRIDINUREAS AS VEGF RECEPTOR KINASE INHIBITORS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2007-07-18 | — | — | EP | disclosed |
| EP-1807415-A2 | NOVEL ANTHRANILAMIDE PYRIDINUREAS AS VEGF RECEPTOR KINASE INHIBITORS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2007-07-18 | — | — | EP | disclosed |
| US-20060264425-A1 | 4-hydroxy-4-methyl-piperidine-1 -carboxylic acid (4-{[2-(2-methyl-2H-indazol-6-ylcarbamoyl)-phenylamino]-methyl}-pyridin-2-yl)-amide; 2,6-dimethyl-morpholine-4-carboxylic acid (4-{[2-(1-methyl-1H-indazol-6-ylcarbamoyl)-phenylamino]-methyl}-pyridin-2-yl)-amide | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2006-11-23 | — | — | US | disclosed |
| US-20060116380-A1 | Novel anthranilamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2006-06-01 | — | — | US | disclosed |
| EP-1657241-A1 | Novel anthranilamide pyridinureas as VEGF receptor kinase inhibitors | Schering Aktiengesellschaft (DE) | 2006-05-17 | — | — | EP | disclosed |
| WO-2006048251-A1 | ANTHRANILAMIDE PYRIDINUREAS AS VEGF RECEPTOR KINASE INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-05-11 | — | — | WO | disclosed |
| WO-2006048248-A2 | NOVEL ANTHRANILAMIDE PYRIDINUREAS AS VEGF RECEPTOR KINASE IMHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-05-11 | — | — | WO | disclosed |
| EP-1655295-A1 | Anthranilamide pyridinureas as VEGF receptor kinase inhibitors | Schering Aktiengesellschaft (DE) | 2006-05-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116380-A1 | Novel anthranilamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors | FLT1, KDR, FLT4 | NOTUM 4331/4885MAOA 968/4885MAOB 1284/4885 |
| US-20110124680-A1 | NOVEL ANTHRANILAMIDE PYRIDINUREAS AS VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) RECEPTOR KINASE INHIBITORS | FLT1, KDR, FLT4 | NOTUM 4331/4885MAOA 968/4885MAOB 1284/4885 |
| US-20060264425-A1 | 4-hydroxy-4-methyl-piperidine-1 -carboxylic acid (4-{[2-(2-methyl-2H-indazol-6-ylcarbamoyl)-phenylamino]-methyl}-pyridin-2-yl)-amide; 2,6-dimethyl-morpholine-4-carboxylic acid (4-{[2-(1-methyl-1H-indazol-6-ylcarbamoyl)-phenylamino]-methyl}-pyridin-2-yl)-amide | KDR, FLT4, FLT1 | NOTUM 4703/4885MAOA 1598/4885MAOB 1919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.